Country: Kanada
Bahasa: Perancis
Sumber: Health Canada
DALBAVANCINE (CHLORHYDRATE DE DALBAVANCINE)
ENDO VENTURES LTD.
J01XA04
DALBAVANCIN
500MG
Poudre pour solution
DALBAVANCINE (CHLORHYDRATE DE DALBAVANCINE) 500MG
Intraveineuse
15G/50G
Prescription
GLYCOPEPTIDES
Numéro de groupe d'ingrédients actifs (GIA) :0160631001; AHFS:
APPROUVÉ
2018-09-04
0RQRUDSKLHHSURXL H DEDYDQFLQH 3DH H 0212*53,( ( 3528,7 ,1 /817/(65(16(,*1(0(176685 /(0e, 0(17 3285 /(3 7,(17 3U ;< /% GDOEDYDQFLQH SRXULQMHFWLRQ PJGHGDOEDYDQFLQH VRXV IRUPHGHFKORUKGUDWHGH GDOEDYDQFLQHIODFRQ 3RXGUHORSKLOLVpHSRXUVROXWLRQ LQWUDYHLQHXVH JHQW DQWLEDFWpULHQ DWHGH UpYLVLRQ DYULO (QGR9HQXUHV/G )LUVW )ORRU 0LQHUYDRXVH 6LPPRQVFRXUW5RDG %DOOVEULGJH XEOLQ ,UODQGH ,PSRU DHXU OOHUJDQ ,QF ERXO (QWHUSULVH 0DUNKDP 2QWDULR /* % LV ULEXHXU /DERUDWRLUHV 3DODGLQ ERXO OH[LV1LKRQ%XUHDX 6W /DXUHQW 4XpEHF 0 3 1XPpURGHFRQWUOHGHODSUpVHQWDWLRQ 0DUTXHGpSRVpHGH OOHUJDQ3KDUPDFHXWLFDOV ,QWHUQDWLRQDO/LPLWHG 0RQRUDSKLHHSURXL H DEDYDQFLQH 3DH H 7%/( 8 (60 7, 5(6 357,( , 5(16(,*1(0(1763285/(352)(66,211(/(/ 617e ,1 , 7,216 (QIDQWV 3HUVRQQHVkJpHV 2175( ,1 , 7,216 3262/2*,((7 0,1,675 7,21 RQVLGpUDWLRQVSRVRORJLTXHV RVHUHFRPPDQGpHHW PRGLILFDWLRQSRVRORJLTXH GPLQLVWUDWLRQ 5HFRQVWLWXWLRQ 68526*( )250(63262/2*,48(6 21(175 7,216 20326,7,21(7 (0% //*( 0,6(6 (1* 5((735e 87,216 3RSXODWLRQV SDUWLFXOLqUHV )HPPHV HQFHLQWHV OODLWHPHQW (QIDQWV 3HUVRQQHVkJpHV ())(76 ,1e6,5 %/(6 SHUoXGHVHIIHWVLQGpVLUDEOHV (IIHWVLQGpVLUDEOHV REVHUYpHV GDQV OHVHVVDLV FOLQLTXHV (IIHWVLQGpVLUDEOHV SHX FRXUDQWVREVHUYpVDX FRXUVGHVHVVDLV FOLQLTXHV 5pVXOWDWVGHODERUDWRLUH DQRUPDX[ KpPDWRORJLTXHFKLPLHFOLQLTXHHW DXWUHV GRQQpHV TXDQWLWDWLYHV ,17(5 7,2160e, 0(17(86(6 ,QWHUDFWLRQVPpGLFDPHQW PpGLFDPHQW ,QWHUDFWLRQV PpGLFDPHQW DOLPHQW ,QWHUDFWLRQV PpGLFDPHQW SODQWHPpGLFLQDOH ,QWHUDFWLRQV PpGLFDPHQW WHVWVGH ODERUDWRLUH 02 ( 7,21(7 3 50 2/2*,( /,1,48( 0RGHG DFWLRQ 3KDUPDFRGQDPLH 3KDUPDFRFLQpWLTXH (175(326*( 67 %,/,7e(7 75 ,7(0(17 357,( ,, ,1)2507,216,(17,),48(6 ,1)250 7,21350 (87,48(6 (66 ,6 /,1,48(6 RQFHSWLRQGHVHVVDLV HW FDUDFWpULVWLTXHV GpPRJUDSKLTXHVGHVpWXGHV 6FKpPD SRVRORJLTXHjGHX[GRVHGH;% PJDXMRXU PJ DX MRXU 5pVXOWDWVGHVpWXGHV 6FKpPDSRVRORJLTXHj GHX[GRVHV GH;< /% PJDXMRXU PJDXMRXU RQFHSWLRQGHOHVVDL HW FDUDFWpULVWLTXHV GpPRJUDSKLTXHVGHOpWXGH 5pJLPH SRVRORJLTXHDYHFXQHGRVHXQLTXHGH ;< /% PJ 5pVXOWDWVGH OpWXGH 5pJLPH SRVRORJLTXH DYHFXQHGRVHXQLTXH GH ;< /% PJ 0, 52%,2/2*,( 72;,2/2*,(1 Baca dokumen lengkap